Skip to main content
$1.46 $0.14 (10.6%)

04:00 PM EDT on 09/30/22

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: No stars

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Current Price $1.46 Mkt Cap $18.3M
Open $1.32 P/E Ratio 0.00
Prev. Close $1.46 Div. (Yield) $0.00 (0.0%)
Daily Range $1.30 - $1.51 Volume 234,780
52-Wk Range $1.01 - $5.85 Avg. Daily Vol. 851,929

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

73 Outperform
9 Underperform
 

All-Star Players

9 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CYCC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

oscillation (76.07)
Submitted June 01, 2015

nev

imrhh (< 20)
Submitted May 06, 2007

This is one of Zack's #1 rated stocks. I do not understand their reasoning for this though. The chart that came up on my computer showed this stock starting at around zero and then going on a very steady decline to at least minus 100%. Call me crazy,… More

Recent Community Commentary

Read the most recent pitches from players about CYCC.

Recs

1
Member Avatar oscillation (76.07) Submitted: 6/1/2015 1:40:33 AM : Outperform Start Price: $8.64 NASDAQ:CYCC Score: -152.64

nev

Recs

2
Member Avatar UnstableEnabled (< 20) Submitted: 12/21/2013 3:30:17 AM : Outperform Start Price: $44.94 NASDAQ:CYCC Score: -193.75

A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.

It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.

Sorely depressed, any good new will cause the stock to surge upward.

Recs

1
Member Avatar toegar2000 (43.66) Submitted: 3/2/2013 10:25:20 AM : Outperform Start Price: $64.19 NASDAQ:CYCC Score: -234.51

Looks good IMO

Leaderboard

Find the members with the highest scoring picks in CYCC.

Score Leader

longtermgrowth09

longtermgrowth09 (21.21) Score: +318.41

The Score Leader is the player with the highest score across all their picks in CYCC.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
longtermgrowth09 21.21 8/3/2010 Underperform 5Y $137.26 -98.94% +219.47% +318.41 0 Comment
mrtofoo 25.17 1/7/2008 Underperform 5Y $425.66 -99.66% +166.01% +265.66 0 Comment
imrhh < 20 5/7/2007 Underperform 3M $637.27 -99.77% +151.79% +251.56 2 Comments
bluebare 28.36 12/7/2012 Underperform 5Y $75.63 -98.07% +153.02% +251.09 0 Comment
MFBurritoSquat 50.76 8/29/2012 11/28/2012 Underperform 1Y $37.47 -96.10% +153.91% +250.02 0 Comment
klaracat 31.20 10/22/2012 Underperform 5Y $60.93 -97.60% +151.02% +248.63 0 Comment
BravoBevo 99.97 3/10/2020 Outperform 5Y $0.50 +192.00% +28.57% +163.43 0 Comment
GenericMind5885 99.42 2/27/2015 Underperform 5Y $17.97 -91.88% +70.11% +161.99 0 Comment
IdahoInvestor 27.84 8/13/2015 Underperform 5Y $7.18 -79.66% +72.16% +151.82 0 Comment
iPittytheFool 37.58 10/10/2016 Underperform 5Y $5.47 -73.31% +66.24% +139.55 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CYCC.